CN105266952A

CN105266952A - A device used in anti-glaucoma surgeries for preventing postoperative conjunctiva adhesion

Info

Publication number: CN105266952A
Application number: CN201410324754.2A
Authority: CN
Inventors: 齐越; 王宁利; 段安丽
Original assignee: Beijing Tongren Hospital
Current assignee: Beijing Tongren Hospital
Priority date: 2014-07-09
Filing date: 2014-07-09
Publication date: 2016-01-27

Abstract

The invention discloses a device used in anti-glaucoma surgery, which comprises a graft made of absorbable material and anti-scar medicine wrapped in the graft. Using the present invention can not only reduce the subconjunctival adhesion after glaucoma surgery through the mechanical barrier effect of the absorbable material, but also prevent the adhesion through the slow release of the anti-scar drug contained in the graft during the absorption of the graft, which can improve The long-term effect of surgery can reduce the failure rate of trabeculectomy.

Description

Device for preventing postoperative conjunctival adhesion used in anti-glaucoma surgery

技术领域 technical field

本发明涉及一种抗青光眼手术中所用防术后结膜粘连的器材，属于医疗器材领域。 The invention relates to a device for preventing postoperative conjunctival adhesion used in anti-glaucoma surgery, belonging to the field of medical devices.

背景技术 Background technique

青光眼是一种不可逆性致盲性眼病，正确治疗可避免眼盲的发生。眼压升高是其主要的危险因素。长期以来，小梁切除术是目前临床上治疗青光眼最主要的手术方法，手术的目的是控制患者的眼压。 Glaucoma is an irreversible blinding eye disease, correct treatment can prevent the occurrence of blindness. Elevated intraocular pressure is its main risk factor. For a long time, trabeculectomy has been the most important surgical method in the clinical treatment of glaucoma. The purpose of the surgery is to control the intraocular pressure of the patient.

在手术中，术后滤过通道周围组织增生粘连，是造成手术失败的主要原因。粘连主要集中在两个位置，一为巩膜瓣周围，一为滤过泡下方的结膜及结膜下组织。尽管目前小梁切除手术的手术方式和术中相关药物、器材已有了很大的发展，但是手术后2年内失败率仍达15%～30%。失败的主要原因与术后滤过通道尤其是巩膜瓣下及巩膜与结膜间瘢痕组织增生有关。 During the operation, postoperative tissue proliferation and adhesion around the filtration channel is the main reason for the failure of the operation. Adhesions were mainly concentrated in two locations, one was around the scleral flap, and the other was the conjunctiva and subconjunctival tissue below the filtering bleb. Although the current trabeculectomy surgery methods and related intraoperative drugs and equipment have been greatly developed, the failure rate within 2 years after surgery is still as high as 15% to 30%. The main reason for the failure was related to the proliferation of scar tissue in the postoperative filtration channel, especially under the scleral flap and between the sclera and the conjunctiva.

因此，需要一种能够在抗青光眼手术中使用用于减少术后结膜粘连的器材。 Therefore, there is a need for a device that can be used in anti-glaucoma surgery to reduce postoperative conjunctival adhesions.

发明内容 Contents of the invention

本发明公开了一种抗青光眼手术中所用器材，包括由可吸收材料构成的植片和包裹在植片内的抗瘢痕药物。 The invention discloses a device used in anti-glaucoma surgery, which comprises a graft made of absorbable material and anti-scar medicine wrapped in the graft.

使用本发明，既可以通过可吸收材料的机械阻隔作用减少青光眼术后结膜下粘连，又能通过植片内包含的抗瘢痕药物在植片吸收中的缓慢释放起到防止粘连的作用，可以提高手术远期效果，降低小梁切除术的失败率。 Using the present invention can not only reduce the subconjunctival adhesion after glaucoma surgery through the mechanical barrier effect of the absorbable material, but also prevent the adhesion through the slow release of the anti-scar drug contained in the graft during the absorption of the graft, which can improve The long-term effect of surgery can reduce the failure rate of trabeculectomy.

附图说明 Description of drawings

图1为本发明一种实施方案的正视图。 Figure 1 is a front view of one embodiment of the invention.

图2为本发明另一种实施方案的正视图。 Figure 2 is a front view of another embodiment of the present invention.

图3为本发明的侧视图。 Figure 3 is a side view of the present invention.

Claims

1. A device used in anti-glaucoma surgery, which comprises a graft made of absorbable material and an anti-scar drug wrapped in the graft.

2. The device according to claim 1, wherein said absorbable material has a body absorption time of more than 3 months.

3. The device according to claim 1, wherein the anti-scar drug is microencapsulated and dispersed in the implant, and the drug is released slowly during the absorption process of the implant.

4. The device of claim 1, wherein said graft is rectangular or trapezoidal.

5. The device according to claim 4, wherein the length and width of the graft are less than 2cm×2cm, and the thickness is less than 1mm.

6. The device according to claim 1, wherein said graft is fixable or free.

7. The device according to claim 3, wherein the size of said microcapsules is less than 500um and the total volume of all microcapsules accounts for at least 50% of the implant volume.